Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice

Starting soon

Conditions studied: Peptic Ulcer, NSAID-Induced Peptic Ulcer

In brief

This study is a prospective, multi-center, observational study to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in real-world clinical practice in Korea. Patients receiving NSAIDs and requiring gastroprotective therapy will be enrolled and followed prospectively. The study will assess patient-reported outcomes (PROs) related to gastrointestinal symptoms, as well as safety outcomes.

Key facts

Study ID

NCT07558707

Run by

Daewoong Pharmaceutical Co. LTD.

People needed

7000

Starts

2026-04-30

Expected to finish

2027-12-31

Last updated by the study team

2026-04-30

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged ≥19 years
• Patients requiring NSAIDs therapy
• Patients requiring prevention of NSAIDs-induced peptic ulcer
• Patients prescribed Fexuclue Tablet 20 mg
• Patients who provide written informed consent

You may not qualify if…

• Hypersensitivity to Fexuclue or its components
• Severe hepatic impairment
• Pregnant or breastfeeding women
• Patients considered inappropriate by investigator

Where it is running

• Multiple centers in Republic of Korea — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.